{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:58:23Z","timestamp":1792511903803,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["308636\/2019\u20138"],"award-info":[{"award-number":["308636\/2019\u20138"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Neurobiology"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.conb.2022.102618","type":"journal-article","created":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T18:42:39Z","timestamp":1660416159000},"page":"102618","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Immunobiology of neuromyelitis optica spectrum disorders"],"prefix":"10.1016","volume":"76","author":[{"given":"Daissy Liliana","family":"Mora Cuervo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisele","family":"Hansel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7695-6020","authenticated-orcid":false,"given":"Douglas Kazutoshi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.conb.2022.102618_bib1","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12974-019-1594-1","article-title":"The history of neuromyelitis optica. Part 2: \u2018Spinal amaurosis\u2019, or how it all began","volume":"16","author":"Jarius","year":"2019","journal-title":"J\u00a0Neuroinflammation"},{"key":"10.1016\/j.conb.2022.102618_bib2","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/bpa.12084","article-title":"Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature","volume":"23","author":"Jarius","year":"2013","journal-title":"Brain Pathol"},{"key":"10.1016\/j.conb.2022.102618_bib3","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.nic.2016.12.010","article-title":"Neuromyelitis optica spectrum disorders","volume":"27","author":"Akaishi","year":"2017","journal-title":"Neuroimaging Clin"},{"key":"10.1016\/j.conb.2022.102618_bib4","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s00401-013-1116-7","article-title":"Presence of six different lesion types suggests diverse mechanisms of tissue injury in neuromyelitis optica","volume":"125","author":"Misu","year":"2013","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.conb.2022.102618_bib5","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.conb.2022.102618_bib6","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1742-2094-9-14","article-title":"Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients","volume":"9","author":"Jarius","year":"2012","journal-title":"J\u00a0Neuroinflammation"},{"key":"10.1016\/j.conb.2022.102618_bib7","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3389\/fneur.2020.00501","article-title":"Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide","volume":"11","author":"Hor","year":"2020","journal-title":"Front Neurol"},{"key":"10.1016\/j.conb.2022.102618_bib8","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41572-020-0214-9","article-title":"Neuromyelitis optica","volume":"6","author":"Jarius","year":"2020","journal-title":"Nat Rev Dis Prim"},{"key":"10.1016\/j.conb.2022.102618_bib9","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1001\/archneur.63.7.964","article-title":"Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression","volume":"63","author":"Pittock","year":"2006","journal-title":"Arch Neurol"},{"key":"10.1016\/j.conb.2022.102618_bib10","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1523\/JNEUROSCI.17-01-00171.1997","article-title":"Specialized membrane domains for water transport in glial cells: high- resolution immunogold cytochemistry of aquaporin-4 in rat brain","volume":"17","author":"Nielsen","year":"1997","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.conb.2022.102618_bib11","doi-asserted-by":"crossref","first-page":"14781","DOI":"10.1073\/pnas.1617859114","article-title":"Tolerance checkpoint bypass permits emergence of pathogenic T cells to neuromyelitis optica autoantigen aquaporin-4","volume":"113","author":"Sagan","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.conb.2022.102618_bib12","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3389\/fncel.2019.00142","article-title":"Role of glutamatergic excitotoxicity in neuromyelitis optica spectrum disorders","volume":"13","author":"Silva","year":"2019","journal-title":"Front Cell Neurosci [Internet"},{"key":"10.1016\/j.conb.2022.102618_bib13","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s40478-015-0259-2","article-title":"Severely exacerbated neuromyelitis optica rat model with extensive astrocytopathy by high affinity anti-aquaporin-4 monoclonal antibody","volume":"3","author":"Kurosawa","year":"2015","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.conb.2022.102618_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.00389","article-title":"Experimental models of neuroimmunological disorders: a review","volume":"11","author":"da Silva","year":"2020","journal-title":"Front Neurol"},{"key":"10.1016\/j.conb.2022.102618_bib15","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1093\/brain\/awac079","article-title":"A\u00a0new form of axonal pathology in a spinal model of neuromyelitis optica","volume":"145","author":"Herwerth","year":"2022","journal-title":"Brain"},{"key":"10.1016\/j.conb.2022.102618_bib16","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12974-016-0717-1","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin","volume":"13","author":"Jarius","year":"2016","journal-title":"J\u00a0Neuroinflammation"},{"key":"10.1016\/j.conb.2022.102618_bib17","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-01294-3","article-title":"Cytoprotective IgG antibodies in sera from a subset of patients with AQP4-IgG seropositive neuromyelitis optica spectrum disorder","volume":"11","author":"Tradtrantip","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.conb.2022.102618_bib18","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.neurol.2020.07.019","article-title":"Area postrema syndrome as initial manifestation in neuromyelitis optica spectrum disorder patients: a retrospective study","volume":"177","author":"Zhou","year":"2021","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.conb.2022.102618_bib19","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s11882-016-0619-4","article-title":"Common and rare manifestations of neuromyelitis optica spectrum disorder","volume":"16","author":"Rosales","year":"2016","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.conb.2022.102618_bib20","first-page":"6","article-title":"Neuromyelitis optica spectrum disorders associated to posterior reversible encephalopathy syndrome: pathogenesis, diagnosis, treatment and evolution: a case report and literature review","volume":"9","author":"Benmoh","year":"2018","journal-title":"J\u00a0Neurol Neurophysiol"},{"key":"10.1016\/j.conb.2022.102618_bib21","doi-asserted-by":"crossref","first-page":"102428","DOI":"10.1016\/j.msard.2020.102428","article-title":"Latin American consensus recommendations for management and treatment of neuromyelitis optica spectrum disorders in clinical practice","author":"Carnero Contentti","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.conb.2022.102618_bib22","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1212\/WNL.0b013e31826aac4e","article-title":"Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype","volume":"79","author":"Kitley","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.conb.2022.102618_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.nano.2022.102531","article-title":"Anti-aquaporin-4 immunoglobulin G colorimetric detection by silver nanoparticles","volume":"41","author":"Higa","year":"2022","journal-title":"Nanomed Nanotechnol Biol Med"},{"key":"10.1016\/j.conb.2022.102618_bib24","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jns.2011.03.038","article-title":"Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures","volume":"306","author":"Jarius","year":"2011","journal-title":"J\u00a0Neurol Sci"},{"key":"10.1016\/j.conb.2022.102618_bib25","doi-asserted-by":"crossref","first-page":"e965","DOI":"10.1212\/NXI.0000000000000965","article-title":"Investigating the presence of interattack astrocyte damage in neuromyelitis optica spectrum disorder","volume":"8","author":"Hyun","year":"2021","journal-title":"Neurol - Neuroimmunol Neuroinflammation"},{"key":"10.1016\/j.conb.2022.102618_bib26","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1136\/jnnp-2018-317969","article-title":"CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications","volume":"89","author":"Kaneko","year":"2018","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.conb.2022.102618_bib27","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1212\/NXI.0000000000001110","article-title":"Demystifying MOGAD and double seronegative NMOSD further with IL-6 blockade","volume":"9","author":"Yong","year":"2022","journal-title":"Neurol Neuroimmunol neuroinflammation"},{"key":"10.1016\/j.conb.2022.102618_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/NXI.0000000000000572","article-title":"Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis?","volume":"6","author":"Stiebel-Kalish","year":"2019","journal-title":"Neurol Neuroimmunol NeuroInflammation"},{"key":"10.1016\/j.conb.2022.102618_bib29","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1007\/s00417-010-1344-7","article-title":"Early high-dose intravenous methylprednisolone is effective in preserving retinal nerve fiber layer thickness in patients with neuromyelitis optica","volume":"248","author":"Nakamura","year":"2010","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.conb.2022.102618_bib30","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/jnnp-2017-316286","article-title":"Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders","volume":"89","author":"Bonnan","year":"2018","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.conb.2022.102618_bib31","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4\u2013positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.conb.2022.102618_bib32","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.conb.2022.102618_bib33","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.conb.2022.102618_bib34","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.conb.2022.102618_bib35","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","article-title":"Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"19","author":"Tahara","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.conb.2022.102618_bib36","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1001\/jamaneurol.2016.1637","article-title":"Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis","volume":"73","author":"Damato","year":"2016","journal-title":"JAMA Neurol"}],"container-title":["Current Opinion in Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095943882200112X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095943882200112X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T13:06:24Z","timestamp":1760706384000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095943882200112X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":36,"alternative-id":["S095943882200112X"],"URL":"https:\/\/doi.org\/10.1016\/j.conb.2022.102618","relation":{},"ISSN":["0959-4388"],"issn-type":[{"value":"0959-4388","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunobiology of neuromyelitis optica spectrum disorders","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Neurobiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.conb.2022.102618","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102618"}}